Direct Bypass Surgery vs. Combined Bypass Surgery for Hemorrhagic Moyamoya Disease: A Comparison of Angiographic Outcomes

Yahui Zhao 1, Shaochen Yu 1, Junlin Lu 1, Lebao Yu 1, Jiaxi Li 1, Yan Zhang 1,2, Dong Zhang 1,2, Rong Wang 1,2 and Yuanli Zhao 1,2*

1 Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, 2 Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China

Objective: Extracranial-intracranial bypass is currently recognized as the optimal treatment for hemorrhagic-type moyamoya disease (MMD) which reduces incidence of rebleeding. Recent studies have reported the advantage of combined bypass over direct bypass for the general MMD patients. However, the effect of direct bypass and combined bypass surgery specifically for hemorrhagic-type MMD had not been investigated yet.

Methods: Hemorrhagic-type MMD patients who underwent direct and combined bypass surgery with complete clinical and radiological documentation from a multicenter cohort between 2009 and 2017 were retrospectively included. Surgical methods included superficial temporal artery-middle cerebral artery (STA-MCA) anastomosis (direct bypass), combined STA-MCA bypass with encephalodurosynangiosis (EDS), and combined STA-MCA bypass with encephaloduroarteriosynangiosis (EDAS). Matsushima standard on follow-up catheter angiography was used to assess surgical outcome. Modified Rankin Scale, incidence of rebleeding and ischemia during follow-up were recorded. Rebleeding-free survival rates between direct and combined bypass were compared by Kaplan-Meier analysis.

Results: Sixty eight hemorrhagic-onset MMD patients were included in this study, among which 71 hemispheres were treated with surgery (direct bypass: 17; bypass+EDS: 24; bypass+EDAS: 30). Forty six (64.8%) hemispheres had satisfactory revascularization (Matsushima level 2–3) and 26 (36.6%) had poor neoangiogenesis. Matsushima level was not significantly different between surgical groups ($P = 0.258$). Good neoangiogenesis from dural grafts was achieved in 26 (36.6%) hemispheres, and good neoangiogenesis from STA grafts was only seen in 4 (out of 30, 12.5%) hemispheres. Multivariate analysis showed bypass patency [$P < 0.001$, OR (95%CI): 13.41 (3.28–54.80)] and dural neoangiogenesis [$P < 0.001$, OR (95%CI): 13.18 (3.26–53.36)] both independently contributed to good angiographic outcome. During follow-up, incidences of rebleeding or ischemic events, and re-bleeding free survival rate were not significantly different between surgical groups ($P = 0.433$, $P = 0.559$,
INTRODUCTION

Moyamoya disease (MMD) is characterized by progressive stenosis and occlusion of the terminal portion of internal carotid artery (ICA) and its main branches, accompanied by formation of collateral network at the base of the brain (1, 2). Manifestations of this rare cerebrovascular entity can be roughly classified into two categories: brain ischemia resulted from compromised cerebral blood flow (ischemic-type) and cerebral hemorrhage due to hemodynamic stress caused by collateral formation (hemorrhagic type) (1, 3, 4). It has been reported that nearly half of adult MMD patients had experienced intracranial hemorrhage (ICH) during disease progression, leading to unfavorable outcome (3, 5, 6). Surgical revascularization has been currently recognized as the optimal treatment for hemorrhagic-type MMD, as it significantly reduces the incidence of recurrent ICH comparing to conservative management (7–11). Direct and combined bypass surgery were reported to be more effective than indirect bypass in preventing rebleeding (12–15), however, the effect and superiority between direct and combined bypass for hemorrhagic-type MMD had barely been investigated yet.

A growing number of studies have suggested that combined bypass surgery provided better revascularization for the general MMD population than direct bypass alone, because the surgical effect was double-secured by both instant increase of blood flow from direct anastomosis and subsequent spontaneous ingrowth of collaterals from the indirect bypass(16–20). However, it was also agreed that treating hemorrhagic MMD with indirect bypass surgery alone might not receive satisfying results (21–23). Our recent study suggested that hemorrhagic-type was an independent risk factor for neoangiogenesis after indirect bypass and poor neoangiogenesis developed in 77.8% hemorrhagic MMD patients (24). On these grounds, whether the indirect part of combined bypass surgery functions as expected for hemorrhagic MMD patients appeared questionable. This study aimed to compare the effect of direct bypass and combined bypass on revascularization for hemorrhagic MMD by evaluating angiographic outcome after surgery, and as far as we are concerned, the current study for the first time investigated the effect and weight of indirect bypass in combined bypass surgery for hemorrhagic MMD.

and $P = 0.997$). However, patients who underwent combined bypass surgery had significantly lower mRS at follow-up comparing to patients who underwent direct bypass ($P = 0.006$).

**Conclusion:** Combined bypass surgery and direct bypass surgery offered similar revascularization for hemorrhagic MMD. Bypass patency and dural angiogenesis both contributed to revascularization independently. The potential of indirect bypass to grow new vessels in hemorrhagic-MMD patients was generally limited, but dural leaflets offered better neoangiogenesis than STA grafts and was therefore recommended for surgical revascularization of hemorrhagic MMD.

Keywords: moyamoya disease, hemorrhagic-type, surgical revascularization, direct bypass, combined bypass, angiographic outcome, surgical outcome

MATERIALS AND METHODS

**Patients Selection**

The participants included in this study were from a multi-center cohort of Han-Chinese MMD patients who had been treated between 2009 and 2017. Patients initially presented with cerebral hemorrhagic events that were treated with direct or combined surgical revascularization and acquired pre-surgical and follow-up digital subtract angiography (DSA) were retrospectively collected and reviewed. Diagnosis was made according to Guideline set by Research Committee on Spontaneous Occlusion of the Circle of Willis (25) based on characteristic findings on angiography of stenosis or occlusion of the terminal portion of ICA and/or proximal portions of the anterior and/or the middle cerebral artery (MCA) accompanied by formation of puff-like vessel networks, with no evidence of other identified etiologies (25). The study was approved by the ethics committee of Beijing Tiantan Hospital and general written informed consent allowing data to be used for research purpose was obtained from all patients at admission.

**Surgical Modalities**

Indication for surgical revascularization was based on the guidelines set by the Japanese Ministry of Health and Welfare (25). Generally, hemispheres with radiological evidence of compromised cerebral blood flow or developed ischemic or hemorrhagic symptoms were considered for revascularization. Specifically, for hemorrhagic MMD, the hemorrhagic side on CT scanning was revascularized in priority. In this study, three types of procedures were performed, including direct bypass, combined direct bypass and encephalodurosynangiosis (EDS), and combined direct bypass and encephaloduroarteriosynangiosis (EDAS). Indirect bypass alone was not performed. Direct bypass was performed as end-to-side anastomosis of branch of the superficial temporal artery (STA) to cortical branches of MCA, with dura mater replaced and sutured anatomically. For combined bypass, EDS or EDAS was performed as well in addition to STA-MCA anastomosis. For EDS, dura was cut in a radial fashion, inverted and inserted underneath the bone edge of the craniotomy. EDAS was a combination of EDS and suturing...
of STA branch onto the brain surface and, in these cases, two branches (anterior and posterior) of STA were both used (Figure 1). Direct bypass patency was routinely confirmed with intraoperative indocyanine green videoangiography during the procedure.

Generally, simple bypass surgery without EDS or EDAS was performed before 2013. Based on the knowledge that combined bypass surgery might be more beneficial for MMD patients, from then on, combined direct bypass and EDS (bypass+EDS) was adopted and after 2015, combined direct bypass and EDAS (bypass+EDAS) was mostly performed, except for patients with one single branch of STA.

**Perioperative Complications and Follow-up**

After surgery, patients were routinely given fluid infusion and blood pressure was controlled under 140/100 mmHg. Antiplatelet therapy was not administered for fear of potential rebleeding. Patients presented with newly-developed neurological symptoms postoperatively were examined by computed tomography (CT) scan and magnetic resonance imaging (MRI) to identify cerebral hemorrhage or infarction.

After discharge, patients were follow-up by clinic visits or by telephone interviews at 3–6 months after surgery and annually thereafter. Doctors performing follow-up assessments were blind to baseline information. Recurrent hemorrhagic or ischemic strokes and modified Rankin Scale (mRS) were documented during follow-up.

**Radiological Evaluations**

DSA follow-ups were scheduled at 6–12 months after surgery. Evaluation of DSA included effect of revascularization, decrease of moyamoya vessels and improvement of anterior choroidal and posterior communicating arteries (AchA-PCoA) dilation. Assessments were conducted by two independent neurosurgeons who were not involved in the surgery. Discrepancies were discussed before a final evaluation was graded. The intrarrater correlation between DSA reads was tested by consistency test and outlined in Table 1.

The general effect of revascularization was evaluated with Matsushima score into four levels as previously described (26, 27): briefly, neoangiogenesis from external carotid artery system covering more than 2/3 of MCA territory was determined as level 3, neoangiogenesis covering more than 1/3 but <2/3 of MCA territory was determined as level 2, neoangiogenesis covering <1/3 of MCA territory was determined as level 1, and no obvious collateral formation was determined as level 0. Based on this, level 0 and 1 were further defined as “Poor” angiographic outcome and levels 2 and 3 were defined as “Good” angiographic outcome. Bypass patency was determined as “Occluded,” “Stenosed,” and “Patent” based on the patency of the anastomosis (as described in Figure 2). Neoangiogenesis from the indirect bypass was determined as “None,” “Minimal,” and “Good” based on the amount and depth of vessel ingrowth, with collaterals growing from dural grafts or from STA grafts evaluated separately (as described in Figure 3). Neoangiogenesis from bur hole drainage was evaluated as “yes” and “no” according to the existence of new vessels.
The number of moyamoya vessels in the capillary phase on the lateral view of DSA was compared between pre-surgical and follow-up angiography. A visible decrease of moyamoya vessels was recorded. Dilation of AchA-PCoA was evaluated based on criteria suggested by Morioka et al. (28) and modified by Liu et al. (29), as seen in Figure 4. Reduction of dilation and branch extension of AChA-PCoA on follow-up DSA was recorded as improvement of AchA-PCoA dilation.

**Statistical Analysis**
Statistical analysis was carried out using SPSS software (v.25.0; IBM Corp., Chicago, IL, USA). Categorical variables were presented as counts (with percentages) and continuous variables...
were presented as the means ± standard deviations. The Pearson chi-square test and Fisher exact test were used to compare categorial variables. One-way ANOVA analyzing was used to compare continuous variables between the groups. Predictors of angiographic outcome were investigated with univariate and multivariate logistic regression and odds ratios (ORs) and 95% confidence intervals (CIs) were presented. Factors influencing bypass patency and neoangiogenesis from indirect bypass were analyzed with logistic regression. Kaplan–Meier survival analysis was used to compare the rebleeding-free survival rates between patients who underwent direct bypass and combined bypass. All the analyses were calculated on a procedure basis and a P value <0.05 was considered statistically significant.

RESULTS

Baseline Characteristics

A total of 68 patients were included in this study. Among them, 3 patients received a bilateral revascularization, making a total of 71 procedures (31 male and 40 female). 17 (23.9%) hemispheres were presented as the means ± standard deviations. The Pearson chi-square test and Fisher exact test were used to compare categorial variables. One-way ANOVA analyzing was used to compare continuous variables between the groups. Predictors of angiographic outcome were investigated with univariate and multivariate logistic regression and odds ratios (ORs) and 95% confidence intervals (CIs) were presented. Factors influencing bypass patency and neoangiogenesis from indirect bypass were analyzed with logistic regression. Kaplan–Meier survival analysis was used to compare the rebleeding-free survival rates between patients who underwent direct bypass and combined bypass. All the analyses were calculated on a procedure basis and a P value <0.05 was considered statistically significant.

Angiographic Outcomes

Among a total of 71 procedures, Matsushima level 3 was achieved in 20 (28.2%) hemispheres, level 2 was achieved in 26 (36.6%) hemispheres, level 1 in 21 (29.6%) hemispheres and level 0 in 4 (5.6%) hemispheres. Direct bypass remained patent in 31 (43.7%) hemispheres whereas 24 (33.8%) bypasses were stenosed and 16 (22.5%) were completely occluded. Regarding the effect of indirect bypass, dural neoangiogenesis was determined as “poor in 15 (21.1%) patients,” “minimal” in 30 (42.3%) patients and “good” in 26 (36.6%) patients. It was noteworthy that in the direct bypass group, although dura was replaced and sutured anatomically instead of inverting and attaching to the brain cortex, a considerable number of hemispheres (4 good and 9 minimal) also developed neoangiogenesis. In the bypass+EDAS group, only 4 (12.5%) had good neoangiogenesis from STA grafts, while 16 (50.0%) had minimal and 12 (37.5%) had none. Among 14 patients that underwent bur hole drainage at the time of hemorrhage, only one (7.1%) still presented collaterals through bur hole at follow-up. Dilation of middle meningeal artery was seen in 25 (35.2%) operated hemispheres. 27 (38.0%) hemispheres had improvement of AchA-PcoA dilation and 46 (64.8%) presented decreased moyamoya vessels. Aforementioned angiographic factors were compared between the three groups with no significant difference found, as seen in Table 3.

Factors Contributing to Good Angiographic Outcome

To investigate the factors contributing to good angiographic outcome (Matsushima level 2–3) for hemorrhagic-type MMD, we conducted univariate and multivariate analysis of surgical and clinical characteristics (Table 4). Factors achieving P < 0.05 in univariate analysis were included in multivariate analysis. Age and STA neoangiogenesis were also included because their influence might not be fully ruled out. In this way, bypass patency [P < 0.001, OR (95%CI): 13.41 (3.28–54.80)] and dural neoangiogenesis [P<0.001, OR(95%CI): 13.18 (3.26–53.36)] were recognized as independent influencing factors, whereas STA neoangiogenesis and age were not independently related with angiographic outcome (P = 0.079 and P = 0.405, respectively).
Factors Influencing Bypass Patency and Dural Neoangiogenesis

Analysis of factors which might affect bypass patency and dural neoangiogenesis were shown in Table 5. Bypass patency was dichotomized as “occluded” and “not occluded” (including “stenosed” and “patent”), and dural neoangiogenesis was dichotomized as “good” and “poor” (including “minimal” and “none”) for logistic regression. Younger age was found significantly related with patent bypass ($P = 0.005$), otherwise no significant association was found. Good dural neoangiogenesis was associated with younger age, history of MMD-related cerebral infarction and diabetes ($P = 0.014$, 0.034, and 0.020, respectively).

Postoperative Complications and Outcomes

Postoperative complications and outcomes at follow-up were demonstrated in Table 6. Combined bypass surgery with additional EDAS took longer time (Bypass+EDAS: 259.47 ± 63.60 min) than other techniques (Bypass+EDS: 232.83 ± 86.73 min; direct bypass: 230.88 ± 62.78 min), but no significant difference was found. One (4.2%) patient in the Bypass+EDS group and 2 (6.7%) in the Bypass+EDAS group had postoperative cerebral hemorrhage. 2 (6.7%) patients in the Bypass+EDAS group had transient neurological deficits (TNEs), and both fully recovered before discharge, including one fluency disorder and one weakness in lower limbs. One (3.3%) patient who underwent Bypass+EDAS had wound infection. The incidence of postoperative complications was not significantly different between the three groups.

In this series, 3 patients were lost to follow-up. The remaining 68 patients were followed for a mean of 21.8 ± 13.7 months (range: 8.1–84.2 months). During follow-up, 4 (5.9%) patients suffered from rebleeding and 3 (4.4%) had ischemic episodes. Three (4.4%) patients had a mRS >3. The incidences of rebleeding and recurrent ischemia during follow-up were not significantly different between the
TABLE 3 | Angiographic outcomes of different surgical types.

| All pts (n = 71) | Direct bypass (n = 17) | Bypass+EDS (n = 24) | Bypass+EDAS (n = 30) | P-value |
|-----------------|------------------------|---------------------|---------------------|---------|
| MATSUSHIMA SCORE |                        |                     |                     |         |
| 0               | 4 (5.6%)               | 2 (11.8%)           | 1 (4.2%)            | 1 (3.3%) | 0.258  |
| 1               | 21 (29.6%)             | 5 (29.4%)           | 6 (25.0%)           | 10 (33.3%) | 0.807  |
| 2               | 26 (36.6%)             | 6 (35.3%)           | 6 (25.0%)           | 14 (46.7%) | 0.692  |
| 3               | 20 (28.2%)             | 4 (23.5%)           | 11 (45.8%)          | 5 (16.7%) |         |
| DIRECT BYPASS PATENCY |          |                     |                     |         |
| Occluded        | 16 (22.5%)             | 4 (23.5%)           | 4 (16.7%)           | 8 (26.7%) |         |
| Stenosed        | 24 (33.8%)             | 6 (35.3%)           | 10 (41.7%)          | 8 (26.7%) |         |
| Patent          | 31 (43.7%)             | 7 (41.2%)           | 10 (41.7%)          | 14 (46.7%) |         |
| INDIRECT BYPASS NEOANGIOGENESIS | |                     |                     |         |
| Dural           |                        |                     |                     |         |
| None            | 15 (21.1%)             | 4 (23.5%)           | 3 (12.5%)           | 8 (26.7%) | 0.247  |
| Minimal         | 30 (42.3%)             | 9 (52.9%)           | 8 (33.3%)           | 13 (43.3%) |         |
| Good            | 26 (36.6%)             | 4 (23.5%)           | 13 (54.2%)          | 9 (30.0%) |         |
| STA Branch      |                        |                     |                     |         |
| None            | 12 (37.5%)             | 3 (8.3%)            | 4 (15.4%)           | 2 (11.1%) |         |
| Minimal         | 16 (50.0%)             | 10 (29.4%)          | 7 (27.3%)           | 5 (23.8%) |         |
| Good            | 4 (12.5%)              | 1 (3.0%)            | 3 (11.1%)           | 2 (10.5%) |         |
| BUR Hole        |                        |                     |                     |         |
| No              | 13 (92.9%)             | 4 (80.0%)           | 4 (100.0%)          | 5 (100.0%) | 0.379  |
| Yes             | 1 (7.1%)               | 1 (20.0%)           | 0 (0.0%)            | 0 (0.0%) |         |
| MMA dilation    | 25 (35.2%)             | 6 (35.3%)           | 11 (45.8%)          | 8 (26.7%) | 0.342  |
| Improvement of AchA-PcoA dilation | 27 (38.0%) | 7 (41.2%) | 8 (33.3%) | 12 (40.0%) | 0.841  |
| Decrease of moyamoya vessels | 46 (64.8%) | 12 (70.6%) | 14 (58.3%) | 20 (66.7%) |         |

MMA, middle meningeal artery.

groups (Table 6). Kaplan-Meier analysis (Figure 5) showed no significant difference in rebleeding-free survival rate between direct bypass group and combined bypass group (P = 0.997) during follow-up. However, more patients who underwent combined bypass surgery had lower mRS score (0-2) at follow-up comparing to patients who underwent direct bypass surgery (P=0.006).

Surgical and Clinical Outcome for Patients With Occluded Bypass
Sixteen patients found with occluded bypass at follow-up were analyzed separately. Because the sample size was very limited, we combined patients underwent two types of combined surgery into one group. The results are shown in Table 7. More patients in the combined bypass group (5, 41.7%) had higher Matsushima level (≥2) than in the direct bypass group (41.7% vs. 25.0%, P = 0.528). Improvement of AchA-PcoA dilation, decrease of moyamoya vessels and mRS at follow-up were not significantly different between the groups.

Case Illustration
Case-1. A 48-years-old male patient who presented with intraventricular hemorrhage underwent combined STA-MCA bypass and EDAS surgery. Follow-up DSA showed direct bypass was almost occluded, yet revascularization was satisfying (Matsushima level 3) due to abundant dural neoangiogenesis. CTP demonstrated improved perfusion at temporal region. This patient had improved symptoms during follow-up. DSA and CTP images are shown in Figure 6.

Case-2. A 50-years-old female patient who presented with intraventricular hemorrhage underwent direct bypass surgery. Follow-up DSA showed patent bypass supplying around 2/3 of MCA territory, leaving a “blank” area in the temporal and parietal region. Dural neoangiogenesis was poor. This patient had a recurrent bleeding 17 months after the surgery. DSA images are shown in Figure 7.

DISCUSSION
Hemorrhagic-type MMD often leads to unfavorable outcome due to devastating recurrent cerebral hemorrhage. Currently, surgical revascularization, especially direct and combined bypass surgery, has been recognized as the optimal treatment for hemorrhagic MMD as they significantly reduce the incidence of rebleeding comparing to conservative management (7–11, 30), however, the
TABLE 4 | Factors affecting angiographic outcome.

| Angiographic Outcome | Uni | Multi | OR (95% CI) |
|----------------------|-----|-------|------------|
| Poor \( (n = 25) \)  |     |       |            |
| Good \( (n = 46) \)  |     |       |            |
| **SURGERY TYPE**     |     |       |            |
| Direct               | 7 (28.0%) | 10 (21.7%) | 0.555 |
| Combined             | 18 (72.0%) | 36 (78.3%) |       |
| **BYPASS PATENCY**   |     |       |            |
| Occluded             | 10 (40.0%) | 6 (13.0%) | <0.001* | <0.001* | 13.41 (3.28–54.80) |
| Stenosed             | 14 (56.0%) | 10 (21.7%) |         |         |                |
| Patent               | 1 (4.0%) | 30 (65.2%) |         |         |                |
| **DURAL NEOANGIOGENESIS** |     |       |            |
| None                 | 10 (40.0%) | 5 (10.9%) | <0.001* | <0.001* | 13.18 (3.26–53.36) |
| Minimal              | 15 (60.0%) | 15 (32.6%) |         |         |                |
| Good                 | 0 (0.0%) | 26 (56.5%) |         |         |                |
| **STA NEOANGIOGENESIS** |     |       |            |
| None                 | 18 (72.0%) | 33 (71.7%) | 0.261 | 0.079 |
| Minimal              | 7 (28.0%) | 9 (19.6%) |         |         |                |
| Good                 | 0 (0.0%) | 4 (8.7%) |         |         |                |
| **PAST HISTORY**     |     |       |            |
| MMD-related TIAs     | 0 (0.0%) | 5 (10.9%) | 0.087 |
| MMD-related infarction | 4 (16.0%) | 11 (23.9%) | 0.435 |
| Hypertension         | 6 (24.0%) | 10 (21.7%) | 0.828 |
| Diabetes             | 0 (0.0%) | 3 (6.5%) | 0.192 |
| Hyperlipidemia       | 1 (4.0%) | 5 (10.9%) | 0.320 |
| Smoking              | 3 (12.0%) | 13 (28.3%) | 0.117 |

Univ, univariate analysis; Multi, multivariate analysis; *P < 0.05.

TABLE 5 | Factors affecting bypass patency and dural neoangiogenesis (multivariate analysis).

| Bypass patency | Dural neoangiogenesis |
|----------------|-----------------------|
| Occluded \( (n = 16) \) | Not-occluded \( (n = 55) \) | P-value | Poor \( (n = 45) \) | Good \( (n = 26) \) | P-value |
| DSA Follow-up time, months | 13.15 | 9.30 ± 7.76 | 0.090 | 9.2707.89 | 11.7278.89w- | 0.445 |
| Age, years | 44.317.89 | 37.42710.94 | 0.005* | 40.93*8.86 | 35.58*8.86 | 0.014* |
| **PAST HISTORY** | | | | | |
| MMD-related TIAs | 0 (0.0%) | 5 (9.1%) | 0.999 | 1 (2.2%) | 4 (15.4%) | 0.108 |
| MMD-related infarction | 4 (25.0%) | 11 (20.0%) | 0.906 | 7 (15.6%) | 8 (30.8%) | 0.034* |
| Hypertension | 4 (25.0%) | 12 (21.8%) | 0.429 | 14 (31.1%) | 2 (7.7%) | 0.099 |
| Diabetes | 0 (0.0%) | 3 (5.5%) | 0.999 | 1 (2.2%) | 2 (7.7%) | 0.020* |
| Hyperlipidemia | 2 (12.5%) | 4 (7.3%) | 0.174 | 4 (8.9%) | 2 (7.7%) | 0.264 |
| Smoking | 4 (25.0%) | 12 (21.8%) | 0.553 | 11 (24.4%) | 5 (19.2%) | 0.294 |

*P < 0.05.

Effect and superiority of these two techniques for hemorrhagic MMD has barely been investigated yet. On the other hand, previous studies suggested that indirect bypass was less effective in preventing rebleeding than direct bypass (12–15, 31). Our recent study also indicated that indirect bypass surgery offered little substantial revascularization for hemorrhagic MMD brain (24), questioning the role of indirect bypass in combined bypass surgery for these patients. Therefore, we conducted the current study to compare the effect of direct bypass and combined bypass on revascularization for hemorrhagic MMD by evaluating angiographic outcome after surgery.

This study included 68 MMD patients with hemorrhagic onset from a multicenter cohort who underwent direct or combined bypass surgery. Surgical revascularization was performed in 71 hemispheres, including 17 simple direct bypass, 24 direct bypass combined with EDS and 30 direct bypass combined with
EDAS. Baseline characteristics were statistically homogeneous between the three surgical groups (Table 2). Our findings showed that combined bypass (either with EDS or EDAS) was not significantly superior than direct bypass surgery in the effect of revascularization for hemorrhagic MMD. On follow-up angiography, revascularization evaluated by Matsushima standard was not significantly different between the three surgical types \( (P = 0.258, \text{Table 3}) \), though more hemispheres underwent combined bypass had higher Matsushima level (bypass+EDS:70.8%, bypass+EDAS:63.4%, bypass alone: 58.8%). No significant difference was found regarding bypass patency, improvement of AchA-PcoA dilation, or decrease of basal moyamoya vessels \( (P = 0.807, 0.841, \text{and } 0.692, \text{respectively}) \), either.

In the long-term, incidences of rebleeding and ischemic events were not significantly different between surgical types (Table 6), and Kaplan-Meier analysis also showed non-significantly different rebleeding-free survival rates between direct and combined bypass surgery \( (P = 0.997, \text{Figure 4}) \). The sudden drop of rebleeding-free rate after the 40-month follow-up in the combined bypass group could be attributed to the uneven follow-up duration, where patients underwent direct bypass were treated earlier and therefore followed longer. However, it was noticeable that more patients who underwent combined bypass achieved better neurological status \( (\text{mRS score } 0–2) \) at long-term follow-up comparing to those who underwent direct bypass \( (P = 0.006, \text{Table 6}) \), suggesting that more obvious improvement

![Diagram](https://via.placeholder.com/150)

FIGURE 5 | Kaplan-Meier plot showing freedom from rebleeding per hemisphere treated with direct and combined bypass surgery. Tick marks indicate time points after which data were censored for a particular patient-hemisphere in the group (point of last follow-up). No significant difference was found between the two surgical groups \( (P = 0.997, \text{Log-Rank test}) \).

| All pts (n = 71) | Surgery type | P-value |
|-----------------|--------------|---------|
| Operation time, min | 243.62 ± 72.36 | 230.88 ± 62.78 | 232.83 ± 86.73 | 259.47 ± 63.60 | 0.291 |
| **POSTOPERATIVE COMPLICATIONS** | | | | |
| Hemorrhagic events | 3 (4.2%) | 0 (0.0%) | 1 (4.2%) | 2 (6.7%) | 0.551 |
| TNEs | 2 (2.8%) | 0 (0.0%) | 0 (0.0%) | 2 (6.7%) | 0.245 |
| Wound Infection | 1 (1.4%) | 0 (0.0%) | 0 (0.0%) | 1 (3.3%) | 0.500 |
| Follow-up | (n = 68) | (n = 16) | (n = 23) | (n = 29) | |
| Rebleeding | 4 (5.9%) | 2 (12.5%) | 1 (4.3%) | 1 (3.4%) | 0.433 |
| Ischemic events | 3 (4.4%) | 0 (0.0%) | 1 (4.3%) | 2 (6.9%) | 0.559 |
| **mRS** | | | | |
| 0–2 | 68 (95.7%) | 13 (81.3%) | 23 (100.0%) | 29 (100.0%) | 0.006* |
| 3–6 | 3 (4.4%) | 3 (18.7%) | 0 (0.0%) | 0 (0.0%) | |

* TNE: transient neurological events; \( *P < 0.05 \).

| Comparing angiographic and clinical outcome of hemisphere s with occluded bypass. | Surgery type | P-value |
|---------------------------------|--------------|---------|
| **MATSUSHIMA SCORE** | | | |
| 0 | 2 (50.0%) | 2 (16.7%) | 0.528 |
| 1 | 1 (25.0%) | 5 (41.7%) | |
| 2 | 1 (25.0%) | 3 (25.0%) | |
| 3 | 0 (0.0%) | 2 (16.7%) | |
| Improvement of AchA-PcoA dilation | 1 (25.0%) | 6 (50.0%) | 0.383 |
| Decrease of moyamoya vessels | 2 (50.0%) | 6 (50.0%) | 1.000 |
| **mRS AT FOLLOW-UP** | | | |
| 0–2 | 3 (75.0%) | 12 (100.0%) | 0.180 |
| 3 | 1 (25.0%) | 0 (0.0%) | |

| TABLE 6 | Postoperative complications and outcome. | All pts (n = 71) | Direct bypass (n = 17) | Bypass+EDS (n = 24) | Bypass+EDAS (n = 30) |
|---------|---------------------------------|---------------|----------------|----------------|----------------|
| **P-value** | | | | | |
| Operation time, min | 243.62 ± 72.36 | 230.88 ± 62.78 | 232.83 ± 86.73 | 259.47 ± 63.60 | 0.291 |
| **POSTOPERATIVE COMPLICATIONS** | | | | | |
| Hemorrhagic events | 3 (4.2%) | 0 (0.0%) | 1 (4.2%) | 2 (6.7%) | 0.551 |
| TNEs | 2 (2.8%) | 0 (0.0%) | 0 (0.0%) | 2 (6.7%) | 0.245 |
| Wound Infection | 1 (1.4%) | 0 (0.0%) | 0 (0.0%) | 1 (3.3%) | 0.500 |
| Follow-up | (n = 68) | (n = 16) | (n = 23) | (n = 29) | |
| Rebleeding | 4 (5.9%) | 2 (12.5%) | 1 (4.3%) | 1 (3.4%) | 0.433 |
| Ischemic events | 3 (4.4%) | 0 (0.0%) | 1 (4.3%) | 2 (6.9%) | 0.559 |
| **mRS** | | | | |
| 0–2 | 68 (95.7%) | 13 (81.3%) | 23 (100.0%) | 29 (100.0%) | 0.006* |
| 3–6 | 3 (4.4%) | 3 (18.7%) | 0 (0.0%) | 0 (0.0%) | |
of neurological function was offered by combined bypass surgery. This might be related to the rather lower rebleeding rate (bypass+EDS:4.3%, bypass+EDAS:3.4%, bypass alone: 12.5%) and better revascularization in combined bypass group. Although these findings were not statistically significant, the potential benefit of combined bypass surgery cannot be totally ruled out.

Regarding the effect of indirect bypass in combined surgery, the current study showed that neoangiogenesis generated from indirect bypass was very limited in hemorrhagic-type MMD patients. In a total of 71 hemispheres, only 26 (36.6%) had satisfying neoangiogenesis from dural grafts, whereas 45 (56.3%) had none or very localized neoangiogenesis. Similarly, in 30 patients who were operated with additional EDAS, only 4 (12.5%) had good ingrowth vessels from STA grafts (Table 3). This finding was in consistency with our previous study of a MMD series treated with indirect revascularization, where neoangiogenesis from indirect bypass in hemorrhagic-type MMD was very little comparing to in ischemic-type (24), confirming our hypothesis that indirect bypass, regardless of being performed alone or combined with direct bypass, was less effective for hemorrhagic-type MMD. Neoangiogenesis through the bur hole was only seen in one hemisphere (of 15 hemispheres had undergone bur hole drainage prior at time of hemorrhage) at follow-up, again supporting the aforementioned viewpoint. Having said that, dural neoangiogenesis was found independently contributing to good revascularization in multivariate analysis [P < 0.001,
FIGURE 7 | Illustrated case 2. A 50-years-old female patient presented with intraventricular hemorrhage (IVH) who underwent direct bypass surgery. (A,B) Preoperative DSA images showed Suzuki stage VI ICA and external carotid artery. (C,D) Postoperative DSA showed patent direct bypass supply most of MCA territory. Dural neoangiogenesis was very limited. This patient had a recurrent IVH during follow-up.

OR (95%CI): 13.18 (3.26–53.36), Table 4] in addition to bypass patency, despite the low chance of collateral growth from indirect bypass in hemorrhagic MMD. Comparatively, STA grafts had very limited influence on angiographic outcome in this series, which might be related to the extremely poor ingrowth from STA grafts, indicating using STA as indirect bypass grafts for hemorrhagic MMD patients might be unnecessary.

As we have mentioned, patency of direct bypass was another significant, and probably the most important, contributor to good revascularization \([P < 0.001, \text{OR (95\%CI): 13.41 (3.28–54.80), Table 4}\)]). For patients with occluded bypass, more patients (5, 41.7%) who underwent combined bypass surgery had better angiographic outcome comparing to patients (1, 25.0%) who underwent direct bypass surgery \((P = 0.528)\). Though sample size was too small to yield any statistical significance, the possibility that indirect bypass would play a role after the direct bypass had been occluded should not be overlooked.

Factors that might influence bypass patency and dural neoangiogenesis were analyzed with multivariate logistic regression (Table 5). Our findings showed age was the most important indicator for revascularization of hemorrhagic MMD patients. Older age was significantly related to occluded bypass \((44.31 \pm 7.64 \text{ vs. } 37.42 \pm 10.94 \text{ years old, } P = 0.005)\), while younger age was associated with good dural neoangiogenesis \((35.58 \pm 12.65 \text{ vs. } 40.93 \pm 8.86 \text{ years old, } P = 0.014)\). This finding was consistent with previous reports on younger patients turn to have better outcome with indirect revascularization \((13, 18, 32)\), yet also indicated the difficulty and dilemma to treat the elderly patients with MMD. Moreover, history of MMD-related infarction was also associated with good dural neoangiogenesis, suggesting that hemorrhagic MMD patients
with cerebral hypoperfusion were more likely to benefit from indirect bypass.

Needless to say, combined bypass surgery was technically more challenged than direct bypass surgery, but our results showed it did not bring additional risks during the postoperative period even though operation time was longer (Table 6). Such finding had also been reported by previous literature (33–35). Knowing that, it seemed that combined bypass surgery might still be preferential for hemorrhagic MMD patients, especially with attaching dura grafts as indirect revascularization. Although, the chance of neoangiogenesis was a little low, when new vessels do grow, it would increase the possibility for hemorrhagic MMD patients to gain good revascularization, providing better outcome without increasing the postoperative risk.

Generally speaking, hemorrhagic-type MMD patients had worse outcome compared to other subtypes of MMD, the treatment of which had also been a dilemma for neurosurgeons (1, 7, 36, 37). In the current series, only 46 (64.8%) had satisfying revascularization after bypass surgery, probably explaining the general unpleasant long-term outcome in hemorrhagic MMD patients. Results from the current study confirmed our previous finding that indirect bypass had a relatively low chance to grow new vessels in hemorrhagic MMD brain. Nevertheless, we do not recommend completely abandoning combined bypass surgery for hemorrhagic MMD, especially the attachments of dural leaflets which most likely would bring additional blood supply and remedy for these patients when the vital bypass is occluded. Future studies investigating predictors and risk factors of neoangiogenesis from indirect bypass in hemorrhagic MMD patients would certainly bring delight to this plight.

Limitation

The current study had a few limitations. First, the study was retrospective, therefore quite a few defects in study design cannot be overlooked, including the limited sample size, retrospective assessments of angiography and loss of patients to follow-up. Baseline characteristics, though statistically homogenous, was not controlled beforehand: the direct bypass group had more female patients with smaller vessels, and mRS at admission was also higher in the direct bypass group, which might have led to biased results. Moreover, the practice of direct bypass was earlier in our center, the possibility that skilled of surgeons might be improved over time could also lead to bias. Secondly, a variety of surgical strategies were used in this study. Even so, only EDS and EDAS were incorporated in combined bypass in the current study because they were the main procedures performed in our institute. The effect of direct bypass combined with encephaloduromyoarteriosynangiosis (EDMAS) and multiple bur hole was not investigated. Last but not the least, the current study was merely an interpretation of clinical materials and experience. The underlying mechanisms of different vessel growth potential in different types of MMD was not explained by us. Further studies are needed to clarify these issues, and hopefully by concerted efforts progress will be made to bring more benefit to MMD patients.

CONCLUSION

For hemorrhagic MMD, combined bypass surgery was not significantly superior than simple direct bypass surgery regarding effect of revascularization and prevention of recurrent strokes. The potential of neoangiogenesis from indirect bypass was poor in hemorrhagic MMD patients, yet neoangiogenesis from dural grafts and bypass patency both contributed to good surgical outcome in these patients. Additional attachments of dural leaflets was recommended for hemorrhagic MMD as combined bypass.

AUTHOR CONTRIBUTIONS

Conception and design: YahZ. Acquisition of data: YahZ, SY, JLu, and JLi. Analysis and interpretation of data: YahZ, LY, and JLi. Drafting the article: YahZ. Technical Supports and Surgery: YanZ, DZ, RW, and YuZ. Critically revising the article: All authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: YuZ. Study supervision: YuZ.

FUNDING

This study was funded by the Ministry of Science and Technology of China, National Key Technology Research and Development Program (2015BAI12B04), by National Natural Science Foundation of China (H0906 81571110 to YuZ) and by the Training Plan of High-Level Technical Talents in Beijing Municipal Bureau of Health (2015-3-041).

REFERENCES

1. Starke RM, Komotar RJ, Hickman ZL, Paz YE, Pugliese AG, Otten ML, et al. Clinical features, surgical treatment, and long-term outcome in adult patients with moyamoya disease. J Neurosurg. (2009) 111:936–42. doi: 10.3171/2009.3.NS08387
2. Hoshino H, Izawa Y, Suzuki N. Epidemiological features of moyamoya disease in Japan. Neurrol Med Chir. (2012) 52:295–8. doi: 10.2176/nmc.52.295
3. Takahashi JC, Miyamoto S. Moyamoya disease: recent progress and outlook. Neurrol Med Chir. (2010) 50:824–32. doi: 10.2176/nmc.50.824
4. Smith ER. Moyamoya arteriopathy. Curr Treat Opt Neurol. (2012) 14:549–56. doi: 10.1007/s11940-012-0195-4
5. Fukui M, Kono S, Sueishi K, Ikezaki K. Moyamoya disease. Neuropathology (2000) 20:561–4. doi: 10.1046/j.1440-1789.2000.00300.x
6. Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol. (2008) 7:1056–66. doi: 10.1016/S1474-4422(08)70240-0
7. Miyamoto S, Yoshimoto T, Hashimoto N, Okada Y, Tsuji I, Tominaga T, et al. Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke (2014) 45:1415–21. doi: 10.1161/STROKEAHA.113.004386
8. Bao XY, Duan L, Yang WZ, Li DS, Sun WJ, Zhang ZS, et al. Clinical features, surgical treatment, and long-term outcome in pediatric patients with moyamoya disease in China. Cerebrovasc Dis. (2015) 39:75–81. doi: 10.1159/000359524

Frontiers in Neurology | www.frontiersin.org 12 December 2018 | Volume 9 | Article 1121
9. Deng X, Gao F, Zhang D, Zhang Y, Wang R, Wang S, et al. Effects of different surgical modalities on the clinical outcome of patients with moyamoya disease: a prospective cohort study. *J Neurosurg.* (2017) 128:1327–37. doi: 10.3171/2016.12.JNS162626

10. Macyzuin L, Attiah M, Ma TS, Ali Z, Faught R, Hossain A, et al. Direct versus indirect revascularization procedures for moyamoya disease: a comparative effectiveness study. *J Neurosurg.* (2017) 126:1523–9. doi: 10.3171/2015.5.JNS15504

11. Wang G, Zhang X, Feng M, Liu X, Guo F. Efficacy of surgical treatment on the recurrent stroke prevention for adult patients with hemorrhagic moyamoya disease. *J Craniofac Surg.* (2017) 28:2113–6. doi: 10.1097/SCS.0000000000004004

12. Dusick JR, Gonzalez NR, Martin NA. Clinical and angiographic outcomes from indirect revascularization surgery for Moyamoya disease in adults and children: a review of 63 procedures. *Neurosurgery* (2011) 68:34–43. doi: 10.1227/NEU.0b013e3181f5c8e2

13. Park SE, Kim JS, Park EK, Shim KW, Kim DS. Direct versus indirect revascularization in the treatment of moyamoya disease. *J Neurosurg.* (2017) 129:480–9. doi: 10.3171/2017.5.JNS17353

14. Shen W, Xu B, Li H, Gao X, Liao Y, Shi W, et al. Encephaloduroarteriosynangiosis for adult intracranial arterial stenosis and occlusion: a systematic review. *Clin Neurol Neurosurg.* (2018) 155:3570–6. doi: 10.3892/etm.2018.5850

15. Rashad S, Fujimura M, Niizuma K, Endo H, Tominaga T. Long-term follow-up of pediatric moyamoya disease treated by combined direct-indirect revascularization surgery: single institute experience with surgical and perioperative management. *Neurol Neurosurg Psychiatry* (2014) 86:1121–5. doi: 10.1136/jnnp-2013-311556

16. Fujimura M, Tominaga T. Lessons learned from moyamoya disease: outcome of direct/indirect revascularization surgery for 150 affected hemispheres. *Neuror Med Chir.* (2012) 52:237–32. doi: 10.2176/nmc.52.237

17. Liu X, Zhang D, Shuo W, Zhao Y, Wang R, Zhao J. Long term outcome after conservative and surgical treatment of haemorrhagic moyamoya disease. *J Neurol Neurosurg Psychiatry* (2013) 84:258–65. doi: 10.1136/jnnp-2012-302236

18. Zhao Y, Li J, Lu J, Zhang Q, Zhang D, Wang R, et al. Predictors of neoangiogenesis after indirect revascularization in moyamoya disease: a multicenter retrospective study. *J Neurosurg.* (in press).

19. Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis; Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). *Neuror Med Chir.* (2012) 52:245–66. doi: 10.2176/nmc.52.245

20. Matsuhashima T, Inoue T, Suzuki SO, Fujiki K, Fukui M, Hasuso K. Surgical treatment of moyamoya disease in pediatric patients—comparison between the results of indirect and direct revascularization procedures. *Neurosurgery* (1992) 31:401–5. doi: 10.1227/00006123-199209000-00003

21. Nakashima H, Meguro T, Kawada S, Hirotsune N, Ohmoto T. Long-term results of surgically treated moyamoya disease. *Clin Neurol Neurosurg.* (1997) 99 (Suppl. 2):S156–61. doi: 10.1016/S0303-8467(97)00056-5

22. Morioka M, Hamada J, Kawano T, Todaka T, Yano S, Kai Y, et al. angiographic dilation and branch extension of the anterior choroidal and posterior communicating arteries are predictors of hemorrhage in adult moyamoya patients. *Stroke* (2003) 34:90–5. doi: 10.1161/01.STR.010047120.67507.0D

23. Liu W, Zhu S, Wang X, Yue X, Zhou Z, Wang H, et al. Evaluation of angiographic changes of the anterior choroidal and posterior communicating arteries for predicting cerebrovascular lesions in adult moyamoya disease. *J Clin Neurol.* (2011) 18:374–8. doi: 10.1016/j.jocn.2010.05.032

24. Huang Z, Ding X, Men W, Zhang D, Zhao Y, Wang R, et al. Clinical features and outcomes in 154 patients with haemorrhagic moyamoya disease: comparison of conservative treatment and surgical revascularization. *Neurol Res.* (2015) 37:886–92. doi: 10.1177/174328151500000073

25. Zhao et al. Direct and Combined Bypass for Hemorrhagic MMD...